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INTRODUCTION
Humans live in a close (''symbiotic'') relationship with an inherent ''microbiome'', comprised of bacteria, archaea, and unicellular eukaryotes. The most densely populated human body habitat is the gastrointestinal tract (GIT). 1 The GIT microbiome plays a myriad of roles vital to human physiology, including digestion of food, synthesis of vitamins, production of short-chain fatty acids, and the prevention of colonization by pathogens through exclusion. 2 In a healthy human GIT, microorganism homeostasis is tightly regulated by the host's immune system. [3] [4] [5] However, various perturbations, such as antibiotic attenuation of sensitive bacteria, may disrupt this balanced state, leading to a state typically referred to as ''dysbiosis'', 3, 6 in which pathogenic microbes can overgrow the community. 6 Furthermore, reduced intestinal barrier function can facilitate translocation of microorganisms and microbial products from the GIT lumen to mesenteric lymph nodes and/or the bloodstream, 7 putting the host at risk for local infections and sepsis. 6, 8 Allogeneic hematopoietic stem cell transplantation (allo-HSCT) represents an effective treatment for several hematological malignancies. Transplantation is preceded by a conditioning regimen, consisting of either total body immune ablative irradiation or high doses of chemotherapy, to facilitate engraftment of transplanted stem cells. Moreover, allo-HSCT is known to greatly impact the stability and integrity of the GIT microbiome, resulting in substantially reduced bacterial diversity and the emergence of dominance by (often drug-resistant) single bacterial taxa. 9 The conditioning treatment for allo-HSCT may also lead to mucositis of the GIT, culminating in the formation of ulcers, dysphagia, and diarrhea. 10 One complication of allo-HSCT is acute graft-versus-host disease (aGvHD), 11 a systemic, inflammatory disease that is provoked by a complex allogeneic immune response, primarily affecting the skin, liver, and GIT. 12 In addition, the GIT microbiome has been implicated in the development and/or exaggeration of aGvHD. Specifically, the damaged GIT epithelial barrier in allo-HSCT patients allows translocation of microorganisms or pathogen-associated molecular patterns (PAMPs). 13 PAMPs can then activate antigen-presenting cells, leading to alloactivation and proliferation of donor T cells that trigger aGvHD. 13 Supportive care of patients receiving allo-HSCT includes prophylactic broad-spectrum antibiotic treatment, 14 an intervention that also selects for potential pathogens carrying antibiotic resistance genes (ARGs), 15 within the GIT microbiome. Such antibiotics also drive horizontal transfer of ARGs among commensal bacteria, often including numerous opportunistic pathogens. 16 Antibiotic treatment has ambiguous effects on treatment outcome. On the one hand, a low bacterial diversity at engraftment, possibly caused by chemotherapy, total body irradiation, and/or broad-spectrum antibiotics, has been linked to AT A GLANCE COMMENTARY Kaysen A, et al.
Background
Allogeneic hematopoietic stem cell transplantation is a therapy for many hematological malignancies. However, its effects on the gastrointestinal tract microbiome remain poorly understood.
Translational Significance
Allogeneic hematopoietic stem cell transplantation and its associated drug treatments have detrimental effects on the gastrointestinal tract microbiome. Antibiotic treatment of these patients gives rise to overgrowth of pathogenic microbes, possessing and expressing antibiotic-resistant genes. Loss of epithelial barrier function likely contributes to bacterial and fungal invasions and activation of inflammatory responses. Enrichment in potentially pathogenic strains through accompanying antibiotic treatment may further contribute to worsening overall treatment outcome through systemic infection. Pathogenic microbes might provide antigens to antigen-presenting cells, activating various immune effectors that associate with acute graftversus-host disease.
detrimental outcomes. 17 On the other hand, GIT decontamination using antimicrobials has been observed to lower the rate of aGvHD. 18, 19 Previous studies have demonstrated altered microbiome community structures directly after allo-HSCT or conditioning treatment. 17, [20] [21] [22] Abnormal bacterial GIT communities, especially following antibiotic treatment, can facilitate expansion of yeasts, including potentially fatal, invasive Candida albicans infections. 23, 24 However, it is not yet known how GIT microbial communities including archaea and eukaryotes evolve over longer periods of time. It is also uncertain how disruption of the microbiome, via antibiotic regimens and aGvHD, affects the human host and overall treatment outcome.
Here, we analyzed in detail the GIT microbiome of patients undergoing allo-HSCT. The main objectives were to describe the changes in the prokaryotic (bacterial and archaeal) community as well as in the eukaryotic subpopulation during treatment. Based on this data, the samples from one patient were subjected to detailed characterization using a combination of highresolution metagenomic (MG) and metatranscriptomic (MT) analyses. Population-and strain-level resolutions highlighted higher expression of ARGs in samples following treatment driven by apparent selection of organisms encoding ARGs. This study serves as a proof-of-concept for future meta-omic studies of the GIT microbiome in the context of allo-HSCT and other intensive medical treatments.
MATERIAL AND METHODS
Study participants and fecal sample collection. This study was approved by the Ethics Review Board of the Saarland Amendments 1 and 2 (Reference Number 37/13) and by the Ethics Review Panel of the University of Luxembourg (Reference Number ERP-15-029). Following written informed consent, 16 patients undergoing allo-HSCT were enrolled in the study.
For microbial diversity and richness analyses, patients were included only if fecal samples were obtained from at least 2 of the following time points: (1) up to 8 days before allo-HSCT (designated time point-1, ''TP1''); (2) directly after allo-HSCT (up to 4 days after allo-HSCT, ''TP2''); and/or (3) shortly after the expected time of engraftment (between days 20 and day 33 after allo-HSCT, ''TP3''). One additional patient was selected for in-depth analysis of treatment effects over an extended period of time. From this patient, fecal samples were collected 13 days before allo-HSCT, as well as 75 and 119 days after allo-HSCT. Fecal samples were immediately flash-frozen onsite and preserved at 280 C to ensure the integrity of the biomolecules of interest.
Extraction of biomolecules from fecal samples. Fecal samples were pretreated as described in HeintzBuschart et al. 25 DNA and RNA were extracted from this pretreated sample as described previously using the DNA/RNA/Protein kit (Qiagen, Hilden, Germany), 26, 27 and additional DNA was obtained using the PowerSoil DNA isolation kit (MO BIO Laboratories, Carlsbad, Calif). Extracted biomolecules were stored at 280 C until sequencing.
16S and 18S rRNA gene amplicon sequencing and data analysis. Amplification and paired-end sequencing of extracted and purified DNA was performed on an Illumina MiSeq platform at the Groupe Interdisciplinaire de G enoprot eomique Appliqu ee (GIGA, Belgium). The V4 region of the 16S rRNA gene, used for identifying bacteria and archaea, and the 18S rRNA gene, used for resolving the eukaryotic community structure, were amplified and sequenced as previously described. 28 16S rRNA gene sequencing reads were processed using the LotuS pipeline 29 (version 1.34) with default parameters. Processed reads were clustered into operational taxonomic units (OTUs), designating taxa with similar amplicon sequences, at an identity level of 97%. For taxonomic assignment of 16S rRNA gene amplicon sequencing data, we used the Ribosomal Database Project classifier. 30 OTUs with a confidence level below 0.8 at the domain level were filtered out as well as OTUs with no more than 10 reads in any given sample.
To process the 18S rRNA gene sequencing reads, a workflow specifically designed to process nonoverlapping reads was used. 31 For classification of 18S rRNA gene amplicon sequencing data, the Protist Ribosomal Reference database 32 was employed. After processing, OTUs with less than 10 reads in all samples were removed, as well as unclassified OTUs and OTUs belonging to the taxon Craniata. For analyses, the 16S and 18S rRNA gene sequencing data were rarefied to the lowest number of respective reads for any sample (16S: 71,051 reads and 18S: 1020 reads).
Statistical analyses and plots were generated in R (version 3.2.1). 33 Microbial alpha-diversity and richness were determined at the OTU level, by calculating the Shannon diversity index and the Chao1 index, using the R package ''vegan''. 34 Statistical comparison of diversity and richness was carried out using the Kruskal-Wallis test, the non-parametric Wilcoxon rank sum test, or, when applicable, the Wilcoxon signed-rank test. Comparisons with P values ,0.05 were considered statistically significant. Differential analyses of taxa, based on 16S rRNA gene sequencing data, were performed using the Bioconductor package DESeq2, 35 combined with the Wald test, after multiple-testing adjustment.
Metagenomic and metatranscriptomic sequencing, processing, and assembly. MG and MT sequencing of the extracted DNA and RNA fractions was conducted by GATC Biotech AG (Konstanz, Germany). Ribosomal RNA (rRNA) was depleted from the RNA fractions using a Ribo-Zero Gold rRNA Removal kit (Illumina, San Diego, Calif). Libraries representing both nucleic acid fractions were sequenced using a 100-bp paired-end approach on an Illumina HiSeq 2500 using HiSeq V3 reagents (Illumina). MG and MT data sets were processed using the Integrated Meta-omic Pipeline (IMP) version 1.1. 36 Further information on this pipeline and on calculations used in this work can be found in Supplementary File 1.
Population-level binning of contigs from the coassembly. To analyze and compare the populationlevel structure of the microbial communities based on the assembled genomic information, contiguous sequences (contigs) were binned. Using VizBin, 37, 38 2D embeddings based on BH-SNE of the contigs of at least 1000 nt were produced, as part of IMP. Population-level clusters 39 were selected as previously described. 25 The resulting bins are hereafter referred to as ''population-level genomes.'' Within a community, the relative size of a populationlevel genome was determined by dividing the number of MG reads mapping to the contigs forming this cluster by the total number of MG reads mapping to all the contigs used in the assembly.
Taxonomic affiliation, reassembly, and sequence comparisons of reconstructed population-level genomes. Taxonomic affiliation, reassembly, and sequence comparisons were performed using a modified workflow of previously described complementary tools and methods. [40] [41] [42] [43] [44] [45] [46] Details are described in Supplementary File 1.
Detection of antibiotic resistance genes. Antibiotic resistance genes (ARGs) within a community or population were searched against Resfams version 1.2 47 using HMMer version 3.1b2. 48 We used the core version of the Resfams database, which includes 119 protein families. 47 In accordance with the HMMer user manual, only genes identified with a bitscore higher than the binary logarithm of the total number of genes (of the community or population) were retained.
Variant identification. Variants were identified in population-level reassembled genomes using SAMtools mpileup 49 with default settings, which include the calling of single nucleotide variants as well as the identification of small insertions/ deletions. The output of SAMtools mpileup was filtered using a conservative heuristic established in Eren et al., 50 which reduces the effect of sequencing errors.
Extraction, sequencing, and analysis of bacterial DNA from a blood culture. DNA was extracted from a blood culture of an organism identified as a multidrugresistant Escherichia coli and sequenced on an Illumina MiSeq, 300 bp paired-end at GIGA. To assess the relationships between different E. coli genomes, PanPhlAn 51 and the provided database, including 118 E. coli reference strains, was applied. In accordance with the PanPhlAn manual, only genes present in 10 or more genomes were further considered.
Availability 
RESULTS
Patient characteristics and treatment. Anthropometric and clinical information of the 10 female and 6 male patients included in the study are provided in Table I . Five patients with relapsed or refractory lymphoma received FluBuCy (fludarabine, busulfan, cyclophosphamide) as conditioning treatment, 6 acute myeloid leukemia (AML) patients received BuCy (busulfan, cyclophosphamide), 1 myeloma, and 1 AML patient received Treo/Flu (treosulfan, fludarabine), 1 AML patient received FluBu (fludarabine, busulfan [total dose 9.6 mg/kg, 3 days of intravenous Bu]), and 2 refractory AML patients received FLAMSA-Bu (fludarabine, amsacrine, busulfan) conditioning treatments. Grafts from 8 fully matched unrelated, 3 single antigen mismatched unrelated, and 5 sibling donors were used. 1.5 years after allo-HSCT, 10 patients were still alive and 6 deceased. Twelve patients developed aGvHD and were treated with corticosteroids (0.5-2 mg/kg/d). Even so, 3 of them progressed to at least grade III aGvHD. 52 As a prophylactic treatment, patients received a fluoroquinolone antibiotic during leukopenia. On the occurrence of fever, patients were treated with piperacillin-tazobactam, followed by meropenem and subsequently vancomycin, if necessary. As antifungal prophylaxis, patients received 200 mg fluconazole. In case of suspected fungal infection, patients also received antifungal treatment with liposomal amphotericin B or caspofungin (Table I) .
Changes within the GIT microbiome of patients undergoing allo-HSCT. We assessed the diversity and richness of the microbial community, separately, for prokaryotic (bacteria and archaea; 16S rRNA gene sequencing) and eukaryotic (18S rRNA gene sequencing) community structures. From TP1 to TP3, the prokaryotic subpopulation drastically and significantly decreased in diversity (2.2-fold reduction, Fig 1, A) and richness (1.3-fold reduction, Fig 1, B) . On the genus level, average decreases of 119-, 47-, and 44-fold relative abundances of the genera Roseburia, Bifidobacterium and Blautia, respectively, were observed from TP1 to TP3 (Fig 1, C) .
At the taxonomic rank of order, decreased Bacteroidales relative abundance was observed in parallel with increased Bacillales (Fig 1, D) . Moreover, we identified only 1 OTU belonging to the domain archaea, the methanogen Methanobrevibacter smithii, 53 that was detected in 13 of 35 total samples (and 10 of 15 patients) with a total of 914 reads. 54 Analysis of the eukaryotic community did not reveal statistically significant differences in Shannon diversity (Fig 1, E) or Chao1 richness (Fig 1, F) , between the different TPs, with no apparent statistically significant difference being observed for the 8 patients undergoing specific antifungal treatments. Overall, around 99% of classified eukaryotic OTUs belonged to the fungal domain, with the majority representing the genera Saccharomyces, Candida, and Kluyveromyces. Only a few different and lowly abundant protists could be identified including Vorticella sp., Prorodon teres, and Phytophthora sp. 54 In summary, we found generally decreased bacterial diversity after allo-HSCT, while the eukaryotic community stayed relatively stable. To further explore the effects of treatment on the structure and function of the GIT microbiome, we applied a detailed meta-omic approach on 1 patient.
Patient A07: description of treatment and status of the patient. Due to the uniqueness of the case, we chose to focus on 1 patient, patient A07, who displayed a marked reduction in bacterial diversity, with high relative abundances of opportunistic pathogens (Fig 2, A and B) and a fatal treatment outcome. This 63-year-old female patient, being treated for AML (with deletion 7q), was refractory to conventional induction (3 1 7) and salvage chemotherapy with high-dose cytarabine and mitoxantrone and, therefore, needed further treatment. As a second-line therapy, FLAMSA-Bu, 55 (Fig  2, D) . She then received peripheral hematopoietic stem cells from a single HLA-C antigen mismatched, unrelated donor. After engraftment on day 26, her bone marrow was hypocellular, but free of leukemia. Further immunosuppression therapy consisted of antithymocyte globulin (anti-T-cell antibodies) from days 24 to 22, mycophenolate mofetil until day 28, and cyclosporine until day 100. Indicating elevated inflammation, a high level of C-reactive protein before and around allo-HSCT was observed, which decreased slightly, but stayed considerably high throughout the entire observation period 54 (Fig 2, C) . After initial onset of neutropenia after allo-HSCT, the leukocyte count increased to 3500/ml 20 days after allo-HSCT, and then further increased to a normal value 80 days after allo-HSCT. However, considerable fluctuations and later a decrease in the leukocyte count was observed 54 (Fig 2, C) .
Since this patient had prolonged neutropenia due to refractory leukemia and intensive chemotherapy, various antibiotics and antifungals were used to treat infectious complications before and during transplantation including piperacillin/tazobactam, meropenem, vancomycin, tigecycline, levofloxacin, ceftazidime and amphotericin B (Fig 2, D) .
74 days after allo-HSCT, the patient developed aGvHD overall grade III, skin stage 2, and GIT stage 3. F) eukaryotes, respectively. The number of samples per collection TP is indicated at the top of each box. Diversity and richness were determined after rarefaction of the data set. Statistically significant decreases in prokaryotic diversity, between TP1 and TP3 (P value 0.014 in Kruskal-Wallis rank sum test), and in prokaryotic richness, between TP1 and TP3 (P value 0.026, Wilcoxon rank sum test), were observed. (C) Changes in the relative abundances of 3 symbiotic bacterial genera between TP1 and TP3. Genera with $1.5-fold decrease, adjusted P values , 0.05, and a relative abundance $5%, in one sample, were included (adjusted P values of 0.0025, 0.026, and 3. Data from all 8 patients who had samples collected at TP1 and TP3 are displayed. TP1 included samples taken (up to 8 days) before allo-HSCT. TP2 included samples taken up to 4 days after transplantation. TP3 included samples taken between days 20 and 33, after transplantation. Significant differences between TPs are indicated by asterisks (*P value , 0.05, **P value , 0.01). allo-HSCT, allogeneic hematopoietic stem cell transplantation.
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As the patient did not respond to 2 mg/kg prednisolone and deteriorated rapidly, antithymocyte globulin (5 mg/ kg) was administered for 4 days as second-line GvHD treatment. Partial remission of intestinal GvHD was noted, with a reduction of diarrhea from .20 stools per day (3500-4500 ml) to 4-5 (formed but soft) stools per day. She was bedridden with general fatigue and malaise. Moreover, signs of infection continued, and due to lower back pain, an MRI scan of the spine was performed, showing a paravertebral abscess, which was surgically removed on day 126. A multidrug-resistant E. coli strain was isolated, both from the abscess and from a blood culture, for further analysis. The patient's health status improved, she was able to walk again, and was discharged from hospital on day 209. However, she was readmitted on day 260 and deceased on day 268, due to GvHD and systemic inflammatory response syndrome, suspected to be bacterial sepsis. However, no pathogen could be recovered from blood cultures.
Patient A07: changes in the microbial community structure during treatment. Fecal samples were taken, as indicated in Fig 2, D , at days 213 (sample ''A07-1''), day 75 (sample ''A07-2''), and day 119 (sample ''A07-3''). Fecal prokaryotic diversity decreased markedly after allo-HSCT (Fig 2, B) . Similarly, in sample A07-1, 177 different OTUs were detected, while A07-2 and A07-3 contained only 62 and 79 OTUs, respectively. Dominant OTUs of sample A07-1, including several OTUs representing Bacteroides spp., Escherichia/ Shigella sp. and Enterococcus sp., reappeared in A07-3 (Fig 2, A) . However, many less-abundant OTUs, belonging to 25 different normal gut genera, disappeared entirely, including Anaerostipes and Clostridium cluster IV. 54 OTUs that were decreased in sample A07-3 (compared with sample A07-1) represented 50 genera, including Alistipes, Barnesiella, Blautia, Clostridium (clusters XIVa and XI), Prevotella, Roseburia, and Ruminococcus. In addition, OTUs belonging to the genus Lactobacillus exhibited a 10-fold increase in relative abundance, while those of Bacteroides spp. increased from 27% to 63% in A07-3 (Fig 2, A) . In total, 19 different OTUs belonging to the genus Bacteroides were detected in the first sample, 23 in the last sample, and only 5 in A07-2, accounting for 0.07% overall. Similar to the short-term changes in the whole cohort, and as described above, the eukaryotic microbial community exhibited no pronounced changes over time (Fig 2, B) . Taken together, we observed a drastic decrease in prokaryotic diversity, with relative expansion of few bacteria, including potential pathogens. To analyze in detail the changes in the GIT microbiome with emphasis on identification of ARGs and strainlevel analysis of specific bacterial populations, coupled MG and MT data sets of samples A07-1 (pretreatment) and A07-3 (post-treatment) were generated. This allows to focus more distinctly on the effects of allo-HSCT and concurrent antibiotic use on the GIT microbiome. The visualizations of the two BH-SNE embeddings (Fig 3, A and B) reflect the drastic change in the GIT microbiome; in particular, the decrease in diversity with the representation of the post-treatment sample A07-3 being exceptionally sparse (Fig 3, B) . In agreement with our 16S rRNA gene sequencing-based results (Fig 2, A) , the most abundant populations in A07-3 were identified as Escherichia coli, Enterococcus faecium, Lactobacillus reuteri, Lactobacillus rhamnosus, and several species from the genus Bacteroides. Also, in accord with those results, most of the clusters were only found in the pretreatment sample (representation of both samples within a single plot, Fig 3, C) .
Given the potential role of opportunistic pathogens in aGvHD, 13 we were specifically interested in 2 population-level reconstructed genomes that were found in both samples, and whose genomes could be recovered with high completeness, namely E. coli and E. faecium.
Evidence for selective pressure at the strain level. The average MG depths of coverage indicated a decreased population size of E. coli after allo-HSCT (in sample A07-3, Fig 4, A) , while that of E. faecium remained rather constant (Fig 4, C) . To reveal possible selective ''sweeps'' in the populations of interest, caused by antibiotics, we performed a gene-wise protein sequence comparison of the different population-level genomes. This analysis revealed that 97.4% of the genes found in the different population-level genomes of E. coli, reconstructed from samples A07-1 and A07-3, were 100% identical, and only 1.1% of the genes were less than 95% identical. In E. faecium, only 76% of the genes were completely identical and 13.2% of the genes showed less than 95% identity. In E. coli, a similarly high number of variants were identified in the pre-and post-treatment samples, with an important overlap of variants identified in both populations (Fig 4, B and E) , whereas only a few variants were present in E. faecium of both samples (Fig 4, D and F) . Observed nucleotide variant frequencies (Fig 4, G and  H) and patterns of variant distributions (Fig 4, E and F) indicated that the treatment may have constituted a genetic bottleneck for E. faecium, culminating in the observed lower genetic diversity. This also suggests that 2 different mechanisms influenced the respective compositions of E. coli and E. faecium populations. While the E. coli population (composed of different strains) remained relatively unaffected, the E. faecium population (mainly represented by a single strain) underwent a selective sweep in response to the antibiotic treatment with selection of a specific genotype expressing ARGs.
Coupled metagenomic and metatranscriptomic analysis of antibiotic resistance genes, in pre-and posttreatment samples from patient A07. ARGs were more often detected post-treatment (0.39% of all genes) than pretreatment (0.28% ARGs, P value 5 6.9 3 10 24 , Fisher's exact test). The relative abundances of ARGs of both the pre-and post-treatment samples were higher (P value 5.601 3 10 27 and 3.278 3 10 210 ) than those in samples from healthy donors (reference healthy microbiomes (RHMs), mean 0.20% 6 0.01% [standard deviation]). Moreover, ARG expression was higher in both samples from patient A07 compared with ARG expression in RHMs (Fig 5, B) .
We were then interested in whether higher numbers of ARGs could also be detected in the specific populations of E. coli and E. faecium. Within the population-level genome of E. coli, 31 ARGs were identified in both samples and 2 additional genes were detected in the post-treatment sample only. In E. faecium, 25 ARGs were identified in both samples of which 21 genes were identical (summaries of the ARGs identified in each population-level genome are listed in Tables II and III) . 54 In E. coli, 20 of the 31 ARGs that were found in both samples exhibited higher levels of expression in the posttreatment sample, while in E. faecium, 18 out of 21 ARGs showed higher expression post-HSCT. 54 Although patient A07 was only treated with antibiotics until day 18 (Fig 2, D) , ARG expression was, in general, higher in the post-treatment sample, both in the whole sample (Fig 5, B) as well as in specific populations (Fig 5, C) .
Genomic characterization of a blood culture E. coli isolate and comparison to GIT populations. The genomes of a blood culture isolate, and GIT population-level genomes of E. coli from patient A07, exhibited an average nucleotide identity of 99.995%. A heatmap and its corresponding dendrogram reflecting the presence and absence of genes in different strains of E. coli indicated that all the E. coli genomes from patient A07, the isolate and the genomes from the GIT MG, were more closely related to each other than to the reference genomes ( Supplementary Fig. S1 ). In the genome of the E. coli isolate, the same ARGs as in the pre-and post-treatment GIT E. coli could be identified, with 4 additional ARGs, compared with the post-treatment GIT E. coli.
DISCUSSION
Short-term structural changes in the gastrointestinal microbiome following allogeneic hematopoietic stem cell transplantation. In this study, we observed that allo-HSCT and its accompanying treatment (including antibiotics), strongly impacted the GIT microbiome, markedly decreasing its bacterial diversity. Moreover, our observed decreased diversity indices agree with values found in an earlier study. 9 Also in accordance with a study focusing on bacterial diversity around engraftment and its association with survival, we found a reduced bacterial diversity shortly after engraftment in patients who did not survive. 17 A significant decrease in important short-chain fatty acid (SCFA) producers [56] [57] [58] (the 3 bacterial genera Roseburia, Bifidobacterium, and Blautia, Fig 1, C) was observed. SCFAs, especially the histone deacetylase inhibitor butyrate, are the main energy source for colonocytes, as well as anti-inflammatory agents which regulate NF-kB activation in colonic epithelial cells and cytokine release. 56 In addition, butyrate induces differentiation of regulatory T cells 59 and enhances the intestinal barrier function by regulating the assembly of epithelial tight junctions, 60 and a recent study showed that local administration of exogenous butyrate mitigated GvHD in mice. 61 Depletion of these important SCFA-producers in the GIT enhances the risk for developing GvHD after allo-HSCT. 22, 62 The ensuing loss of intestinal barrier integrity facilitates translocation of pathogenic bacteria and PAMPs, activating antigenpresenting cells and consequently CD8 1 T cells. We further found that fungi were the most prominent eukaryotes in the GIT microbiome, and that the eukaryotic diversity was stable during treatment (including antibiotic and antifungal treatment), despite changes in bacterial subpopulations. However, antibiotic treatment may indirectly increase the risk for invasive fungal infections, by opening niches to these organisms, which were previously occupied by commensal bacteria. 23, 63 In this patient cohort, we did not observe strong treatment-induced effects on eukaryotic communities. Nevertheless, these organisms remain important for future studies as their overgrowth has previously been linked to adverse treatment outcomes. 24 Long-term effect of allogeneic stem cell transplantation on the gastrointestinal microbiome. Employing detailed integrated meta-omic analyses, we demonstrated the effects of allo-HSCT and accompanying treatment on the GIT microbiome over an extended period of time.
Only one study to date has followed the GIT microbiome trajectory up to 3 months after allo-HSCT. 64 Contrary to that study, which showed that the richness and metabolic capacity of the microbial community recovered after 2 months, 64 we found that the GIT microbial community never fully regained its initial composition, even 4 months after allo-HSCT, with dysbiosis likely conducing to detrimental treatment outcomes. Diversity remained decreased and many bacterial taxa remained absent or drastically decreased, including bacteria whose presence in the human GIT associate with health-promoting properties (such as butyrate production) and whose absence has been linked to negative consequences (such as inflammation). [65] [66] [67] The genus Blautia, for instance, has been linked to reduced aGvHD-associated mortality and improved overall survival, 22 while Barnesiella effectively blocked intestinal domination by vancomycin-resistant enterococci in allo-HSCT patients. 68 On the other hand, potential pathogens, like Fusobacterium sp. and Proteus sp., appeared only in the post-treatment sample. Also, loss in intestinal barrier integrity may have allowed a GIT-borne E. coli to cause a paravertebral abscess ( Supplementary  Fig. S1 ).
Identification of antibiotic resistance genes in population-level genomes of opportunistic pathogens and evidence for selective pressure at the strain level. A higher ratio and expression of ARGs within the microbial community was observed post-treatment, even several months following antibiotic treatment (Fig 5, A and B). Strains that carry or horizontally acquired mutations which lead to higher expression of ARGs might have been selected for by the antibiotic treatment. 69 Overall, our observations indicate that antibiotic pressure, and its associated selection of bacteria encoding ARGs, is likely an essential factor in governing the observed expansion of opportunistic, drug-resistant, pathogens.
Interestingly, the multidrug-resistant E. coli, isolated from a post-allo-HSCT blood culture, was closely related to the GIT-borne E. coli populations. The overlap of ARGs identified in each genome further indicated their association. These findings demonstrate the potential fatal effects of dysbiosis-associated pathogen dominance of the GIT microbiome, and subsequent systemic infections on allo-HSCT patient survival.
CONCLUSION
We observed drastic changes in the composition of the gastrointestinal microbiome of patients after allo-HSCT and supportive care, driven mainly by a decrease in bacterial diversity, but only limited changes in eukaryotes and archaea. Pronounced changes in community structure, especially decreased diversity and expansion of potential pathogens, along with translocation of pathogens and PAMPs could affect overall treatment outcome. Here, we applied novel high-resolution molecular methods to describe the different ways in which GIT bacterial populations respond to antibiotic stress. We identified an increased number and expression of ARGs linked to specific potentially pathogenic strains of clinical relevance during allo-HSCT. Such information could be used to individually tailor patient treatment. Sustaining or restoring diversity, either by: (1) limiting the usage of broad-spectrum antibiotics; (2) fecal microbiome transplantation; and/or (3) administration of specific probiotics could help to increase tolerance or improve the overall efficacy of the therapy.
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